| 张向向,庄 华,吴 昊.卡介苗联合PD-L1抑制剂促进膀胱癌免疫应答研究进展[J].中国肿瘤,2018,27(11):862-866. |
| 卡介苗联合PD-L1抑制剂促进膀胱癌免疫应答研究进展 |
| Progress on BCG Combined with PD-L1 Inhibitors Promoting Immune Response of Bladder Cancer |
| 投稿时间：2018-09-22 |
| DOI：10.11735/j.issn.1004-0242.2018.11.A009 |
|
 |
| 中文关键词: 卡介苗 PD-L1抑制剂 膀胱癌 免疫应答 |
| 英文关键词:BCG PD-L1 inhibitors bladder cancer immune response |
| 基金项目:兰州市城关区科技局科技攻关类项目（2017KJGG0052）；2015年度第二批院内博士科研基金（ynbskyjj2015-2-7） |
|
| 摘要点击次数: 2485 |
| 全文下载次数: 522 |
| 中文摘要: |
| 摘 要：膀胱内灌注衰减活菌卡介苗（Bacillus Calmette-Guérin ，BCG）是中、高风险无肌层浸润膀胱癌患者的主要治疗方式。自卡介苗成功地用于非肌层浸润膀胱癌治疗之后，膀胱癌的治疗未见显著进步，尤其是局部进展和转移性膀胱癌的治疗效果仍不理想。最近，程序性死亡配体-1（PD-L1）和程序性死亡受体-1（PD-1）抑制剂已被证实在膀胱肿瘤中具有良好的耐受性，而且能显著改善局部进展和晚期膀胱癌患者的预后。文章就卡介苗联合PD-L1抑制剂促进膀胱癌免疫应答研究进展作一综述。 |
| 英文摘要: |
| Abstract：Intravesical instillation of attenuated live BCG(Bacillus Calmette-Guérin) vaccine is the main treatment modality for moderate to high risk bladder cancer patients without myometrial invasion. Since BCG has been successfully used in the treatment of non-myometrial invasive bladder cancer，there has been no significant improvement in the treatment of bladder cancer，especially in locally advanced and metastatic bladder cancer. Recently，programmed death ligand-1(PD-L1) and programmed death receptor-1(PD-1) inhibitors have been shown to be well tolerated in bladder cancer and to significantly improve the prognosis of local progression and advanced bladder cancer patients. This article reviews the progress of BCG combined with PD-L1 inhibitors in promoting the immune response of bladder cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |